AFL · 10-Q · 2026Q3 · Full report

Product Launch and Transition

AFLAC INC · 2026-11-05 · Importance 34 · Surprise 42

Aflac Japan’s portfolio centers on third-sector cancer, medical and other health products, which the company expects to remain important as pressure on Japan’s healthcare system drives a continued need for these products. In the third quarter, cancer products accounted for 55.5% of new annualized premium sales, while medical and other health products represented 14.9%. First-sector products Tsumitasu and WAYS are aimed at younger customers and may create opportunities to cross-sell third-sector coverage. Tsumitasu represented 25.2% of third-quarter sales, compared with 0.5% for WAYS.